INTERVIEW: Abbott Nutrition Revs Up For Bigger India Play
This article was originally published in PharmAsia News
Executive Summary
A combination of factors is aiding Abbott Nutrition’s pitch for a bigger slice of the evolving Indian nutrition market. The company is already growing at a rate far higher than the industry average of 12%, a pace it expects to maintain for the next few years.
You may also be interested in...
Ten Months On, Abbott, Wockhardt Terminate Deal For Nutritional Business
MUMBAI - Pharmaceuticals-to-diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt jointly agreed to call off the $130 million deal for a nutritional business that the two had announced barely 10 months ago
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.